2025-08-19 - Analysis Report
Okay, here's the analysis of TG Therapeutics Inc (TGTX), presented in a format suitable for a concise investment report.

## TG Therapeutics Inc (TGTX) Analysis

**Ticker:** TGTX
**Company Description:** TG Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 47.92%
*   **VOO Cumulative Return:** 100.85%
*   **Absolute Divergence:** -30.5
*   **Relative Divergence:** 11.4 (Indicates TGTX's current divergence is near the lower end of its historical range compared to VOO.)

**Analysis:** TGTX has significantly underperformed the S&P 500 over the period.  A relative divergence of 11.4 suggests the underperformance is near the lower end of its historical deviations.

### Alpha/Beta Analysis

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|------------|-------:|------:|--------:|-------:|---------:|
| 2015-2017  |  -6     |  56.5 |   -35   |   -0.1 |      1.3 |
| 2016-2018  |  -8     |  58.6 |   -26   |    0   |      0.7 |
| 2017-2019  |  74     |  58.6 |    44   |    0   |      1.8 |
| 2018-2020  | 402     |  58.6 |   382   |   -0.4 |      8.2 |
| 2019-2021  | 125     |  63.5 |    76   |   -0.5 |      3   |
| 2020-2022  |  -76    |  70.4 |   -78   |   -0.6 |      1.9 |
| 2021-2023  | -350    |  70.4 |  -368   |   -0.8 |      2.7 |
| 2022-2024  |  71     |  73.1 |    45   |   -0.9 |      4.8 |
| 2023-2025  |  55     |  73.1 |     2   |    0.4 |      4.4 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) varies significantly, indicating volatile performance.
*   **MDD:**  The Maximum Drawdown (MDD) is consistently high, highlighting substantial risk.
*   **Alpha:**  Alpha is generally negative, suggesting underperformance relative to its benchmark (VOO). However, there are periods of significant positive alpha.
*   **Beta:**  Beta values fluctuate around zero, indicating TGTX's price movements are not strongly correlated with the overall market.
*   **Cap(B):** Represents market capitalization in Billions.

### 2. Recent Stock Price Movement

*   **Current Price:** 27.73
*   **Previous Close:** 28.08
*   **Change:** -1.25
*   **5-Day Moving Average:** 27.714
*   **20-Day Moving Average:** 31.5445
*   **60-Day Moving Average:** 35.1506

**Analysis:** The stock price is currently below its 5, 20, and 60-day moving averages, indicating a short-term downtrend.  The small price change, price drop from the previous close suggests a slight recent sell-off.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3285 (Low Risk)
*   **RSI:** 21.73 (Oversold)
*   **PPO:** -0.972
*   **Hybrid Signal:** cash_64%_Sell 9.1% of holdings (206 shares - Caution - MRI:0.33) (Cash Ratio: 64% on 2025-07-29)
*   **Recent Relative Divergence Change (20-day):** -0.6 (Short-term decrease)
*   **Expected Return (%):** -223.7%

**Analysis:**

*   **MRI:** The MRI indicates low market risk, which is somewhat contradictory to other indicators.
*   **RSI:** The RSI is in oversold territory, suggesting a potential for a short-term bounce.
*   **PPO:** The PPO value indicates price is falling.
*   **Hybrid Signal:** The hybrid signal suggests reducing holdings and increasing cash, indicating a cautious outlook.
*   **Recent Relative Divergence Change:** The negative change in relative divergence confirms the recent underperformance trend.
*   **Expected Return:**  The extremely negative expected return suggests significant concerns about the long-term outlook for TGTX compared to the S&P 500.

### 4. Recent News & Significant Events

*   **[2025-08-16]** Major business developments, regulatory changes, or market events impacting TGTX.
*   **[2025-08-19]** Analysts discussing TGTX's recent performance and outlook.
*   **[2025-08-15]** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-08-17]** Experts highlight risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The news suggests recent events are causing volatility and are under scrutiny by analysts. Investors are advised to monitor the news closely.

### 5. Recent Earnings Analysis

| 날짜       |   EPS | 매출      |
|------------|------:|:----------|
| 2025-08-08 |  0.19 | 0.14 B$   |
| 2025-05-09 |  0.03 | 0.12 B$   |
| 2024-11-07 |  0.03 | 0.08 B$   |
| 2024-08-09 |  0.05 | 0.07 B$   |
| 2025-08-08 |  0.05 | 0.07 B$   |

**Analysis:** Earnings per share (EPS) has varied. Revenue is on an upward trend, but the recent EPS data shows that the most recent values are relatively lower compared to recent EPS values.

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin   |
|------------|:---------|:----------------|
| 2025-06-30 | $0.14B   | 86.58%          |
| 2025-03-31 | $0.12B   | 87.14%          |
| 2024-12-31 | $0.11B   | 85.77%          |
| 2024-09-30 | $0.08B   | 88.86%          |
| 2024-06-30 | $0.07B   | 88.70%          |

| Quarter    | Equity   |    ROE |
|------------|:---------|-------:|
| 2025-06-30 | $0.28B   | 10.20 |
| 2025-03-31 | $0.24B   |  2.13 |
| 2024-12-31 | $0.22B   | 10.49 |
| 2024-09-30 | $0.19B   |  2.02 |
| 2024-06-30 | $0.18B   |  3.87 |

**Analysis:**

*   **Revenue:** Revenue is generally increasing.
*   **Profit Margin:** Profit margins are consistently high, suggesting strong cost control or pricing power.
*   **Equity:** Equity is increasing over the period.
*   **ROE:** Return on Equity (ROE) shows some volatility, but generally indicates reasonable profitability.

### 7. Overall Assessment

TG Therapeutics Inc. (TGTX) presents a mixed picture:

*   **Negatives:** Significant underperformance compared to the S&P 500,  negative expected return, recent downtrend in stock price, and analyst caution.
*   **Positives:** Growing revenue, high profit margins, oversold RSI (potential for short-term rebound), and news events may provide catalysts.
*   **Conclusion:** Based on this analysis, TGTX appears to be a high-risk investment.  The negative expected return and underperformance suggest significant concerns. While there are some positive financial metrics, the technical indicators and recent news warrant caution. Investors should closely monitor news, earnings, and technical indicators before making any investment decisions. The hybrid signal of 64% cash and selling 9.1% of holdings further reinforces a cautious stance.
